One of the most successful strategies to target Alzheimer’s disease is the development of agents that effectively interact with key enzymes involved in cholinergic dysfunction, especially acetylcholinesterase (AChE). The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.